【摘要】 目的　探讨CYFRA 2 1 1在血清中的表达及其对非小细胞肺癌的诊断、病情监测及疗效判定的临床应用价值。方法分别在手术、放疗或化疗前后 2周内采集非小细胞肺癌患者血清标本共 16 9份。采用放射免疫分析方法检测样本血清中CYFRA2 1 1的表达情况。结果　非小细胞肺癌患者血清CYFRA 2 1 1总体表达水平为 (12 .98± 7.34) μg/L ,其中鳞癌为 (2 0 .48± 11.2 5 )μg/L ,腺癌为 (5 .48± 3 .43) μg/L ,且随病情的发展而升高。检测总体阳性率为 5 6 .80 % ,其中鳞癌为 70 .96 % ,腺癌为 2 6 .32 %。鳞癌患者血清表达水平及检测阳性率均显著高于腺癌患者 (P <0 .0 5 ) ,血清CYFRA 2 1 1的表达水平在术后 2周显著下降 (P <0 .0 5 )。病情稳定、疗效较好的患者血清CYFRA 2 1 1表达无明显变化 ,病情进展、疗效较差的患者则明显升高 (P <0 .0 5 )。结论　CYFRA 2 1 1表达水平对非小细胞肺癌的诊断、病情监测及疗效判定均有较好的临床应用价值更多还原

【Abstract】 Objective To study the clinical significance of CYFRA 21-1 as a serum tumor marker in diagnosis,evaluation of clinical status and prognosis of non-small-cell lung cancer(NSCLC).Methods CYFRA 21-1 in serum sample of 169 patients with NSCLC was analysed by radioimmunoassay in two weeks,before and after treatment of operation,radiotherapy and chemotherapy.Results The serum level of CYFRA 21-1 were 12.98±7.34 μg/L in NSCLC,20.48±11.25 μg/L and 5.48±3.43 μg/L(±s),in squamous-cell carcinoma and adenocarcinoma respectively and increased with TNM staging(P<0.05).The total positive rate was 56.80% for NSCLC,70.96% for squamous-cell carcinoma and 26.32% for adenocarcinoma before any treatment(P<0.01).The serum level of CYFRA 21-1 in the patient with treatment of surgery was markly dicreased in 2 weeks after operation(P<0.05).The serum level of CYFRA 21-1 was no changed in 51 patients without operation whose condition was stable and it was significantly increased in 72 patients with progressive disease.Conclusion CYFRA 21-1 can be used as an useful tumor marker of NSCLC in diagnosis,evaluation of therapeutic effect,and the prognosis.更多还原